AIM: To investigate the enhancement of anti-tumor effect of HSP-MUC1 by self-designed type C CpG-ODN BW005. METHODS: The immunostimulatory effect of CpG-ODN BW005 was detected by IFN protection assay and (3)H proliferation assay in vitro. Sixty C57BL/6 mice were separated into 5 groups randomly, including Sodium Chloride control, HSP-MUC1 control, HSP-MUC1/1585, HSP-MUC1/1826 and HSP-MUC1/BW005. Mice were injected s.c. with agents on day 0, 14 and 28 and were implanted MUC1-EL4 tumor cells s.c. on day 33. Tumor growth and murine death were recorded. Blood was collected in 57 day from tail vein. Subtype of anti-HSP and anti-MUC1 IgG in serum was detected by indirect ELISA. RESULTS: CpG-ODN BW005 could stimulate the proliferation of hPBMC and mice spleoncyte and IFNalpha production. HSP-MUC1/BW005 postponed tumor development, with the average tumor-developed day of 44.8, and prolonged the survival of mice with the average survival day of 49.5. Moreover, final tumor-developed rate of this group was 33.33%, which was the lowest; final survival rate of this group was 66.67%, which was the highest. Levels of anti-HSP and anti-MUC1 IgG2a in HSP-MUC1/CpG-ODNs group were enhanced. CONCLUSION: CpG-ODN BW005, a kind of type C CpG-ODN, could enhance the anti-tumor effect of HSP-MUC1.
AIM: To investigate the enhancement of anti-tumor effect of HSP-MUC1 by self-designed type C CpG-ODN BW005. METHODS: The immunostimulatory effect of CpG-ODN BW005 was detected by IFN protection assay and (3)H proliferation assay in vitro. Sixty C57BL/6 mice were separated into 5 groups randomly, including Sodium Chloride control, HSP-MUC1 control, HSP-MUC1/1585, HSP-MUC1/1826 and HSP-MUC1/BW005. Mice were injected s.c. with agents on day 0, 14 and 28 and were implanted MUC1-EL4 tumor cells s.c. on day 33. Tumor growth and murinedeath were recorded. Blood was collected in 57 day from tail vein. Subtype of anti-HSP and anti-MUC1 IgG in serum was detected by indirect ELISA. RESULTS: CpG-ODN BW005 could stimulate the proliferation of hPBMC and mice spleoncyte and IFNalpha production. HSP-MUC1/BW005 postponed tumor development, with the average tumor-developed day of 44.8, and prolonged the survival of mice with the average survival day of 49.5. Moreover, final tumor-developed rate of this group was 33.33%, which was the lowest; final survival rate of this group was 66.67%, which was the highest. Levels of anti-HSP and anti-MUC1IgG2a in HSP-MUC1/CpG-ODNs group were enhanced. CONCLUSION: CpG-ODN BW005, a kind of type C CpG-ODN, could enhance the anti-tumor effect of HSP-MUC1.